AXNX

Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021

Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator

Axonics® Receives FDA Approval Further Expanding MRI Labeling

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Stock

Axonics® Announces Upsize and Pricing of Public Offering of Common Stock

Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript